Dual-targeting of brain tumors with nanovesicles

Dual-targeting of brain tumors with nanovesicles Nazanin Kianinejad Department of Pharmaceutical Sciences, College of Pharmacy, Health Professions Division, Nova Southeastern University, Fort Lauderdale, FL, USA http://orcid.org/0000-0001-5592-0638 Young Min Kwon Department of Pharmaceutical Sciences, College of Pharmacy, Health Professions Division, Nova Southeastern University, Fort Lauderdale, FL, USA http://orcid.org/0000-0002-9935-4866

The delivery of chemotherapies to brain tumors faces the difficult task of crossing the blood-brain barrier (BBB).1-4 The brain capillary endothelial cells (BCECs) along with other cell lines, such as astrocytes and pericytes, form the BBB. This highly selective semipermeable barrier separates the blood from the brain parenchyma. The BBB controls the movement of drug molecules in a selective manner5 and maintains central nervous system (CNS) homeostasis. Depending on the properties of drugs such as their hydrophilic-lipophilic balance (HLB), some can cross the BBB through passive diffusion.6 However, this approach alone has not led to successful drug developments due to low net diffusion rates and systemic toxicity. Although the use of nanomedicine has been proposed to overcome these drawbacks, many recent studies still rely on the so-called ‘enhanced permeability and retention (EPR)’ effect though there is a realization in the field of drug delivery that EPR effect may not be sufficient for successful drug delivery to brain tumors. Since, compared to many other solid tumors, brain tumors pose additional challenges such as more restrictive blood-tumor barrier as well as the well-developed lymphatic drainage, the selection of functional moieties on the nanocarriers under consideration must be carried out with care to propose better solutions to this challenge.
12 31 2022 01 01 2023 1 3 1 10.34172/crossmark_policy bi.tbzmed.ac.ir false Tabriz University of Medical Sciences Tabriz University of Medical Sciences 2022-03-15 2022-06-21 2022-12-31 10.34172/bi.2022.26321 20230108213043 https://bi.tbzmed.ac.ir/Article/bi-26321 https://bi.tbzmed.ac.ir/PDF/bi-13-1.pdf https://bi.tbzmed.ac.ir/PDF/bi-13-1.pdf https://bi.tbzmed.ac.ir/PDF/bi-13-1.pdf https://bi.tbzmed.ac.ir/PDF/bi-13-1.pdf https://bi.tbzmed.ac.ir/PDF/bi-13-1.pdf 10.4155/tde-2019-0077 10.1080/17425247.2019.1614911 10.1016/j.nano.2017.07.009 10.1016/j.apsb.2014.03.001 10.1038/s41571-019-0177-5 10.1080/17512433.2021.1887729 Matsumura, Y. and H. Maeda. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46(12 Pt 1): p. 6387-92. 10.1016/j.jconrel.2014.03.057 10.1016/j.jconrel.2016.11.015 10.1002/ca.20887 10.1016/j.ebiom.2015.08.019 10.1016/j.pneurobio.2017.08.007 10.1155/2015/198175 10.1016/j.ejpb.2014.01.006 10.1007/s00018-005-5231-z 10.1021/acsomega.0c05500 10.1039/C9NA00056A 10.1016/j.ejps.2018.07.055 10.1016/j.biomaterials.2013.03.097